Latest News

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advanc...

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duv

Teva to Present at the Upcoming Investor Conferences in March

Teva to Present at the Upcoming Investor Conferences in March

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Ext...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable eff...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecu...

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and ...

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adole

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Deliv...

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitilig...

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitilig...

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's...

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Rati

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on Januar...

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28,

Teva Releases Q4 2025 Aide Memoire

Teva Releases Q4 2025 Aide Memoire